Physician profile
Barry L Meyer
NPI 1558368126
$2,803.60
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $415 · 2021: $612 · 2022: $358 · 2023: $26.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $633.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $302.78 | 2019-2022 | |
| Pfizer INC. | $297.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $255.43 | 2019-2023 | |
| Amarin Pharma, INC. | $247.36 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $198.36 | 2019-2021 | |
| Boston Scientific Corporation | $196.81 | 2019-2020 | |
| Edwards Lifesciences Corporation | $141.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $95.14 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.93 | 2019-2021 | |
| Biosense Webster, INC. | $88.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.87 | 2019 | |
| Bardy Diagnostics, INC. | $52.00 | 2021-2022 | |
| Abbott Laboratories | $26.85 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.01 | 2019 | |
| Akcea Therapeutics, INC. | $15.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.